When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Common warts

Evidence last reviewed: 14 Feb 2026
Topic last updated: 30 Oct 2024

Summary

Определение

Анамнез и осмотр

Ключевые диагностические факторы

  • presence of risk factors
  • lesion growth over weeks to months
  • round, raised papule
  • tiny black dots on surface of lesion
Полная информация

Другие диагностические факторы

  • satellite lesions
  • fingers or nail fold lesions
  • facial lesions
  • fissuring
  • hyperkeratosis
  • grayish-white or light brown color
  • filiform papule with sharp spikes
Полная информация

Факторы риска

  • water immersion
  • occupations involving handling of meat or fish
  • nail biting
  • age under 35 years
  • immunocompromised
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • no initial test
Полная информация

Исследования, проведение которых нужно рассмотреть

  • skin biopsy
  • immunoperoxidase stain
  • skin culture
Полная информация

Алгоритм лечения

Острый

common wart: immunocompetent

common wart: immunocompromised

filiform wart

Составители

Авторы

Angela Yen Moore, MD

Director

Arlington Center of Dermatology

Primary Investigator

Arlington Research Center

Arlington

Clinical Assistant Professor

Baylor University Medical Center

Dallas

Clinical Assistant Professor

University of Texas Medical Branch

Galveston

TX

Раскрытие информации

Dr. Moore receives funds as an advisory board member (A), consultant (C), clinical study investigator (I), and speaker (SP) – for Abbvie (I,SP), Almirall (C,I,SP), Arcutis (I), Biofrontera (C,I), Boehringer Ingelheim (I), Bristol-Myers Squibb (C,I), Dermavant (I), DS Biopharma (I), Eli Lilly (I), EpiHealth (A), Evolus (A), Galderma (I), Incyte (I), Janssen (I), Leo (A,SP), Mayne Pharma (C,I), Nimbus (I), Novartis (I), Parexel (I), Pfizer (I,SP), UCB (I), Verrica (I), Vyne (I,SP).

Выражение благодарностей

Dr Angela Yen Moore would like to gratefully acknowledge Dr Leonid Izikson, the previous contributor to this topic. LI declares that he has no competing interests.

Рецензенты

Brenda L. Pellicane, MD

Dermatologist

Wayne State University School of Medicine

Department of Dermatology

Detroit

MI

Раскрытие информации

BLP declares that she has no competing interests.

David Cassarino, MD, PhD

Assistant Professor

Department of Pathology and Laboratory Medicine

University of California

Los Angeles

CA

Раскрытие информации

DC declares that he has no competing interests.

Jashin J. Wu, MD

Chief Dermatology Resident

University of California

Irvine

CA

Раскрытие информации

JJW declares that he has no competing interests.

Sam Gibbs, FRCP

Consultant Dermatologist

Dermatology Department

The Great Western Hospital

Swindon

UK

Раскрытие информации

SG declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

Lipke MM. An armamentarium of wart treatments. Clin Med Res. 2006;4:273-293.Полный текст  Аннотация

Gibbs S, Harvey I, Sterling J, et al. Local treatments for cutaneous warts: systematic review. BMJ. 2002;325:461.Полный текст  Аннотация

Kwok CS, Gibbs S, Bennett C, et al. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012;(9):CD001781.Полный текст  Аннотация

Dall'oglio F, D'Amico V, Nasca MR, et al. Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol. 2012;13:73-96. Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности